Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yoshihiro Komeya is active.

Publication


Featured researches published by Yoshihiro Komeya.


Annals of Nuclear Medicine | 2008

Quantitative evaluation of norcholesterol scintigraphy, CT attenuation value, and chemical-shift MR imaging for characterizing adrenal adenomas

Teruaki Yoh; Makoto Hosono; Yoshihiro Komeya; Sung-Woon Im; Ryuichiro Ashikaga; Taro Shimono; Norio Tsuchiya; Masahiro Okada; Kazushi Hanada; Yukinobu Yagyu; Yasumasa Nishimura; Takamichi Murakami

ObjectiveThe objective of our study was to evaluate diagnostic ability and features of quantitative indices of three modalities: uptake rate on norcholesterol scintigraphy, computed tomography (CT) attenuation value, and fat suppression on chemical-shift magnetic resonance imaging (MRI) for characterizing adrenal adenomas.MethodsImage findings of norcholesterol scintigraphy, CT, and MRI were reviewed for 78 patients with functioning (n = 48) or nonfunctioning (n = 30) adrenal masses. The norcholesterol uptake rate, attenuation value on unenhanced CT, and suppression on in-phase to opposed-phase MRI were measured for adrenal masses.ResultsThe norcholesterol uptake rate, CT attenuation value, and MR suppression index showed the sensitivity of 60%, 82%, and 100%, respectively, for functioning adenomas of <2.0 cm, and 96%, 79%, and 67%, respectively, for those of ≥2.0 cm. A statistically significant correlation was observed between size and norcholesterol uptake, and between CT attenuation value and MR suppression index. Regarding norcholesterol uptake, the adenoma-to-contralateral gland ratio was significantly higher in cortisol releasing than in aldosterone-releasing adenomas.ConclusionsThe norcholesterol uptake rate was reliable for characterization of adenomas among adrenal masses of ≥2.0 cm. CT attenuation value and MR suppression index were well correlated with each other, and were useful regardless of mass size.


Annals of Nuclear Medicine | 2012

Impact of CT attenuation correction by SPECT/CT in brain perfusion images

Kazunari Ishii; Kohei Hanaoka; Masahiro Okada; Seishi Kumano; Yoshihiro Komeya; Norio Tsuchiya; Makoto Hosono; Takamichi Murakami

PurposeThe aim of this study was to elucidate the regional differences between brain perfusion single photon emission computed tomography (SPECT) images reconstructed with a uniform attenuation correction using Chang’s method (AC-Chang) and a non-uniform attenuation correction with CT using SPECT/CT (AC-CT).MethodsSPECT images of a phantom with and without head holder were obtained, and reconstructed images of AC-Chang and AC-CT were compared. Twenty-eight consecutive patients with brain disease examined by SPECT/CT brain perfusion imaging were selected, and images were reconstructed with AC-Chang and AC-CT. The AC-Chang and AC-CT reconstructed images were then compared by voxel-based analysis using three-dimensional stereotactic surface projections.ResultsCounts in the frontal area of the AC-Chang phantom image with head holder were higher than those in the posterior area. Counts in the frontal area of the AC-Chang clinical images were significantly higher than those in the AC-CT images, while the counts in the margin of the frontal lobe and posterior margin of the parietal, occipital cortices and cerebellum of the AC-Chang images were significantly lower. Relative frontal perfusion was 5.0% higher and relative cerebellar perfusion was 4.6% lower in the AC-Chang images relative to the AC-CT images, on average.ConclusionWe demonstrated the frontal dominant hyper-perfusion and parieto-occipital and cerebellar hypo-perfusion in brain SPECT images reconstructed with AC-Chang compared to those reconstructed with AC-CT. We suggest that to obtain an accurate attenuation-corrected brain perfusion SPECT image, attenuation correction by Chang’s method is inadequate.


Nuclear Medicine Communications | 2011

Fluorodeoxyglucose uptake in the bone marrow after granulocyte colony-stimulating factor administration in patients with non-Hodgkinʼs lymphoma

Kohei Hanaoka; Makoto Hosono; Kimio Usami; Yoichi Tatsumi; Yuzuru Yamazoe; Yoshihiro Komeya; Norio Tsuchiya; Kazunari Ishii; Mitsugu Sumita

PurposeTo clarify the change in the fluorodeoxyglucose (FDG) uptake by the bone marrow over time after administration of granulocyte colony-stimulating factor (G-CSF), we evaluated the correlation between the interval from the last day of administration of G-CSF to positron emission tomography/computed tomography (PET/CT) study and spinal bone marrow accumulation in patients with non-Hodgkins lymphoma. MethodsA total of 127 patients with confirmed non-Hodgkins lymphoma who underwent FDG PET within 60 days from the last administration of G-CSF were retrospectively reviewed. Thirty age-matched and sex-matched healthy controls were also included to evaluate physiological FDG uptake. PET/CT examinations were retrospectively reviewed, and maximum standardized uptake value (SUVmax) was measured by placing volumetric regions of interest over each thoracic and lumbar vertebra on PET images referring to CT images. Bone marrow SUV was defined as the mean SUVmax of the vertebra. The correlation between the interval after G-CSF and the bone marrow SUV was plotted and analyzed with polynomial approximation. ResultsIn controls, physiological bone marrow SUV of the spine was determined. In patients with lymphoma, bone marrow SUV decreased over time and reached a plateau at about 14 days after G-CSF administration, and this was higher by 5% than the plateau at 10 days. SUV declined to the ‘physiological range’, that is, mean+1 standard deviation of patients, at about 7 days. ConclusionFor a PET/CT study, an interval of 10 days after G-CSF administration is recommended to minimize the influence of G-CSF on the bone marrow when evaluating treatment response in patients with non-Hodgkins lymphoma.


Nuclear Medicine Communications | 2006

Regional cerebral blood flow in the assessment of major depression and Alzheimer's disease in the early elderly.

Kazushi Hanada; Makoto Hosono; Takashi Kudo; Yoshie Hitomi; Yukinobu Yagyu; Eiji Kirime; Yoshihiro Komeya; Noa Tsujii; Kazuhiko Hitomi; Yasumasa Nishimura

BackgroundAlzheimers disease and major depression are representative diseases that present forgetfulness and a depressive mood. It is often difficult to make a differential diagnosis between the two in the initial phase. AimTo evaluate the differential diagnosis method using regional cerebral blood flow patterns with a three-dimensional stereotactic surface projection technique. MethodsTwenty early-elderly patients with mild and moderate forgetfulness were studied. Among them, 10 were diagnosed as having major depression (the MD group) and the other 10 as having Alzheimers disease (the AD group). All patients underwent cerebral perfusion single photon emission computed tomography (SPECT) with [123I]iodoamphetamine. A z-score was calculated for each pixel of the cerebral surface. Twenty-one circular regions of interest (ROIs) were placed on the z-score map. The significance of the statistical difference in ROI values between the two groups was determined by using the two-sided Mann–Whitney U-test. ResultsThe z-scores for the lateral parietal, lateral temporal, bilateral precuneus and bilateral posterior cingulate gyrus were significantly reduced in the AD group compared with those in the MD group. The z-scores for the lateral frontal, left thalamus and bilateral medial frontal regions were significantly lower in the MD group than in the AD group. ConclusionOur study demonstrated a difference in regional cerebral blood flow patterns between the early elderly with Alzheimers disease and those with major depression. All patients were classified into the appropriate categories using discriminant analysis and z-scores of frontal and parietal regions. Brain perfusion SPECT was a useful tool for the differential diagnosis between Alzheimers disease and major depression.


Annals of Nuclear Medicine | 2010

Decreased brain FDG uptake in patients with extensive non-Hodgkin’s lymphoma lesions

Kohei Hanaoka; Makoto Hosono; Taro Shimono; Kimio Usami; Yoshihiro Komeya; Norio Tsuchiya; Yuzuru Yamazoe; Kazunari Ishii; Youichi Tatsumi; Mitsugu Sumita

ObjectiveFaint brain [18F]fluoro-2-deoxyglucose (FDG) uptake has sporadically been reported in patients with FDG-avid large or diffusely extended tumors. The purpose of this study was to investigate whether there is a correlation between massive tumor uptake and decreased brain uptake on FDG positron emission tomography/computed tomography (PET/CT).MethodsSixty-five patients with histologically confirmed non-Hodgkin’s lymphoma who underwent FDG-PET/CT were enrolled. Thirty control subjects were also included to evaluate normal brain FDG uptake. PET/CT examinations were retrospectively reviewed. The volumetric regions of interest were placed over lesions by referring to CT and PET/CT fusion images to measure mean standardized uptake value (SUVavg). The products of SUVavg and tumor volume were calculated as total glycolytic volume (TGV). The maximum SUV (SUVmax) and SUVavg were measured in the cerebrum and cerebellum. The values of TGV and brain FDG uptake were plotted and analyzed with a linear regression method.ResultsIn the lymphoma patients, there were statistically significant negative correlations between TGV and brain SUVs.ConclusionDemonstrating a significant negative correlation between TGV and brain uptake validated the phenomenon of decreased brain FDG uptake. Diversion of FDG from the brain to the lymphoma tissue may occur during the FDG accumulation process. Recognition of this phenomenon prevents unnecessary further neurological examinations in such cases.


Annals of Nuclear Medicine | 2009

Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions

Masahiro Okada; Taro Shimono; Yoshihiro Komeya; Rina Ando; Yuki Kagawa; Takashi Katsube; Masatomo Kuwabara; Yukinobu Yagyu; Seishi Kumano; Izumi Imaoka; Norio Tsuchiya; Ryuichiro Ashikaga; Makoto Hosono; Takamichi Murakami


Society of Nuclear Medicine Annual Meeting Abstracts | 2008

Evaluation of lymph node metastases in esophageal cancer with SUV correction for partial volume effect on FDG PET/CT

Yuki Kagawa; Makoto Hosono; Yoshihiro Komeya; Kohei Hanaoka; Usami Usami; Yamazoe Yuzuru; Sung-Woon Im; Norio Tsuchiya; Masahiro Okada; Takamichi Murakami


Society of Nuclear Medicine Annual Meeting Abstracts | 2008

FDG uptake in bone marrow after G-CSF administration in patients with malignant lymphoma

Kouhei Hanaoka; Makoto Hosono; Kimio Usami; Yuzuru Yamazoe; Mitsugu Sumita; Yoshihiro Komeya; Norio Tsuchiya; Sung-Woon Im; Masahiro Okada


The Journal of Nuclear Medicine | 2014

Heterogeneity of intratumoral In-111-Zevalin and FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell lymphoma

Makoto Hosono; Kohei Hanaoka; Kazunari Ishii; Kenta Sakaguchi; Sung-Woon Im; Norio Tsuchiya; Yoshihiro Komeya; Yoichi Tatsumi; Itaru Matsumura


The Journal of Nuclear Medicine | 2013

Heterogeneity of CD20 antigen expression and glucose metabolism in correlation with therapeutic response in radioimmunotherapy for B-cell lymphoma

Makoto Hosono; Kohei Hanaoka; Kazunari Ishii; Sung-Woon Im; Kenta Sakaguchi; Yukinobu Yagyu; Yoshihiro Komeya; Norio Tsuchiya; Yoichi Tatsumi; Itaru Matsumura

Collaboration


Dive into the Yoshihiro Komeya's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge